Prostate Cell News Volume 7.35 | Sep 23 2016

TOP STORY

Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1

V-Src transformation of primary murine prostate epithelial cells increased the proportion of prostate cancer stem cells as characterized by gene expression, epitope characteristics and prostatosphere formation. [Cancer Res] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3

Scientists identified an RNA helicase gene, DDX3, which is over-expressed in prostate cancers, and whose expression is directly correlated with high Gleason scores. Knockdown of DDX3 in aggressive prostate cancer cell lines DU145 and 22Rv1 resulted in significantly reduced clonogenicity. [Cancer Res] Abstract

Restoration of Tumor Suppression in Prostate Cancer by Targeting the E3 Ligase E6AP

Researchers have examined the role of the E6-associated protein-promyelocytic (E6AP) leukemia protein axis in prostate cancer (PC). They showed that knockdown of E6AP expression attenuates growth of PC cell lines in vitro. [Oncogene] Abstract

Beta-Adrenergic Signaling Promotes Tumor Angiogenesis and Prostate Cancer Progression through HDAC2-Mediated Suppression of Thrombospondin-1

Using xenograft models, the authors showed that chronic behavioral stress and beta-adrenergic signaling promote angiogenesis and prostate cancer progression. Histone deacetylase-2 (HDAC2) was induced by beta-adrenergic signaling in vitro and in mouse xenografts. [Oncogene] Abstract

A Conjugate of Methotrexate and an Analog of Luteinizing Hormone Releasing Hormone Shows Increased Efficacy against Prostate Cancer

Scientists synthesized a bioconjugate of the LHRH analog [DLys⁶]-LHRH and the anti-tumor agent methotrexate and tested the hypothesis that [DLys⁶]-LHRH-MTX targets and inhibits prostate cancer cell growth in vitro and in vivo. [Sci Rep] Full Article

Global Analysis of Transcription in Castration-Resistant Prostate Cancer Cells Uncovers Active Enhancers and Direct Androgen Receptor Targets

Investigators analyzed direct transcription programs of the androgen receptor (AR) in VCaP cells using global nuclear run-on sequencing (GRO-seq) and integrated the GRO-seq data with the AR-binding sites and VCaP cell-specific TF-binding data. [Sci Rep] Full Article

The Other Face of miR-17-92a Cluster, Exhibiting Tumor Suppressor Effects in Prostate Cancer

Investigators showed that the expression of miR-17-92a miRNAs are reduced in cancerous prostate tissues compared to uninvolved areas and also in aggressive prostate cancer cells. [Oncotarget] Full Article

Targeting Prostate Cancer Cells with Genetically Engineered Polypeptide-Based Micelles Displaying Gastrin-Releasing Peptide

Researchers reported the genetic engineering of a self-assembling nanoparticle based on elastin-like polypeptide, which has been fused with gastrin releasing peptide. These nanoparticles increased intracellular calcium concentrations when added to gastrin releasing peptide receptor positive PC-3 prostate cancer cells, demonstrating specific receptor activation. [Int J Pharm] Abstract | Graphical Abstract

Role of OATP Transporters in Steroid Uptake by Prostate Cancer Cells In Vivo

Investigators sought to determine whether organic anion transporting polypeptide (OATP)-mediated steroid transport can measurably alter prostate cancer androgen levels in vivo. [Prostate Cancer Prostatic Dis] Abstract

Autoregulated Expression of p53 from an Adenoviral Vector Confers Superior Tumor Inhibition in a Model of Prostate Carcinoma Gene Therapy

The authors presented an adenoviral vector where p53 is employed to regulate its own expression and which outperforms a traditional vector when tested in a model of gene therapy for prostate cancer. [Cancer Biol Ther] Abstract

CLINICAL RESEARCH

Dutasteride for the Prevention of Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia: Results of a Phase III Randomized Open-Label 3-Year Trial

High-grade prostatic intraepithelial neoplasia (HGPIN) is a potential precursor of prostate cancer (PCa), and patients with HGPIN are at high risk for PCa development. The authors sought to evaluate the efficacy of dutasteride 0.5 mg in PCa prevention among men with isolated HGPIN on biopsy. [World J Urol] Abstract

Epigenetic Modulators as Therapeutic Targets in Prostate Cancer

The authors discuss the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management. [Clin Epigenetics] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Biocept’s Proprietary Liquid Biopsy Platform to Be Featured at Two Upcoming Molecular Diagnostics Conferences

Biocept, Inc. announced that Lyle Arnold, Ph.D., Chief Scientific Officer of Biocept, will present at two SelectBio conferences. Dr. Arnold’s presentations will focus on Biocept’s patented Target-Selector^™ technology, which uses liquid biopsy to detect and monitor tumor biomarkers to aid physicians in making treatment decisions for patients with cancer. [Press release from Biocept, Inc. discussing research to be presented at the Liquid Biopsies and Minimally-Invasive Diagnostics 2016 Conference, San Diego] Press Release

GenomeDx’s Decipher GRID and Decipher Tests to Be Featured in Multiple Presentations at ASTRO 2016

GenomeDx Biosciences announced that eight presentations featuring Decipher Genomics Resource Information Database (Decipher GRID^®) and the Decipher^® Prostate Cancer Classifier Tests will be presented. [Press release from GenomeDx Biosciences discussing research to be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Boston] Press Release

Precision Biopsy Expands the Clinical Trial of Its ClariCore^™ Biopsy System in Prostate Cancer Patients

Precision Biopsy announced that its application for an Investigational Device Exemption was approved by the U.S. Food and Drug Administration, allowing the company to expand its clinical trial for the ClariCore™ Biopsy System by enrolling prostate cancer patients in the transrectal ultrasound and MR/fusion arms of its study. ClariCore is designed to provide accurate, real-time classification of prostate tissue during biopsy procedures. [Precision Biopsy] Press Release

U of T Mississauga Launches Centre for Medicinal Chemistry

The University of Toronto Mississauga has launched an interdisciplinary centre for the development of new drugs targeting cancer and other diseases, thanks to a $7 million donation from Mississauga-based Orlando Corporation. [The University of Toronto Mississauga] Press Release

Facebook Couple Commits $3 Billion to Cure Disease

Facebook co-founder Mark Zuckerberg and his wife, physician and educator Priscilla Chan, have enlisted a ‘dream team’ of scientific leaders to oversee a US $3-billion effort to boost basic research. [Nature News] Editorial

Titanic Clash over CRISPR Patents Turns Ugly

Much of the focus is on the teams centred at Berkeley and the Broad Institute, whose ‘foundational’ patents cover a wide swathe of CRISPR–Cas9 applications. Although Berkeley’s team filed for a patent first, the Broad opted for an expedited review process, and its patents were granted earlier. [Nature News] Editorial

Spain Joins Bandwagon for ‘Openness’ About Animal Research

The Spanish scientific community has pledged to become more transparent about animal research. Ninety research centers, universities, scientific societies, and companies around Spain have adopted a set of standards, launched by the Confederation of Spanish Scientific Societies, on how research organizations should open up communication channels about their use of laboratory animals. [Science Insider] Editorial

New Fellowship Aims to Increase Diversity in the Life Sciences

A new program aims to launch the careers of life scientists from underrepresented groups by providing up to 8 years of support, covering both the postdoctoral training and junior faculty stages. The Howard Hughes Medical Institute’s Hanna H. Gray Fellows Program will award up to 15 recipients with $60,000 of salary support and $20,000 in flexible funds paid to their institutions for each of up to 4 years of postdoc training. [Science Insider] Editorial

NEW Global Forum on Transplantation Research and Technologies
November 28-30, 2016
Dubai, United Arab Emirates

Visit our events page to see a complete list of events in the community.

NEW PhD Student – Molecular Pathways of Prostate Cancer Progression (German Cancer Research Centre – Helmholtz Association)

Postdoctoral Fellow – Prostate Cancer Biology (University of Maryland)

Chair of Medical Biology (Masaryk University)

Postdoctoral Fellow(s) – Uterine Fibroids and Prostate Cancer (University of Texas Health Science Center at San Antonio)

Research Intern – Prostate Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Researcher – Prostate Cancer (Oregon Health & Science University)

Professor – Prostate Cancer Research (Boston University School of Medicine)

Postdoctoral Researcher – Tumor Biology (LSU Health Sciences Center)

Research Scientist – Functional Cancer Genomics (Institute of Oncology Research – Bellinzona)

Senior VP and Director Clinical Research – Oncology (Fred Hutchinson Cancer Research Center)

Associate Editor (PLOS ONE)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.